Abbvie’s ‘Skyrizi’ has expanded its indication to psoriatic arthritis. As the fourth interleukin inhibitor to receive approval for the indication, Skyrizi has set out to overtake the market with its convenience in administration.

On the 9th, Abbvie Korea has held a ‘Press Conference to celebrate Skyrizi’s indication expansion to psoriatic arthritis’ online. Skyrizi, which was first approved for moderate-to-severe plaque psoriasis in 2019, added the psoriatic arthritis indication on the 5th of last month. Skyrizi may be used to treat adult patients with active psoriatic arthritis who had responded inadequately or were intolerant to disease-modifying anti-rheumatic drugs (DMARDs).

Pr